Genetic strategy to decrease complement activation with adenoviral therapies

BACKGROUND: A major obstacle to using recombinant adenoviral vectors in gene therapy is the natural ability of human adenovirus to activate the classical and alternate complement pathways. These innate immune responses contribute to hepatic adenoviral uptake following systemic delivery and enhance t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gentile, Christopher M., Borovjagin, Anton V., Richter, Jillian R., Jani, Aditi H., Wu, Hongju, Zinn, Kurt R., Warram, Jason M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485611/
https://www.ncbi.nlm.nih.gov/pubmed/31026285
http://dx.doi.org/10.1371/journal.pone.0215226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485611/
https://www.ncbi.nlm.nih.gov/pubmed/31026285
http://dx.doi.org/10.1371/journal.pone.0215226

Ejemplares similares